Our data revealed an enrichment of SMYD3 in residual tumors that had not undergone complete regression after irinotecan exposure, further suggesting that increased expression of SMYD3 may contribute to the cellular mechanisms that mediate cancer chemoresistance (Fig. 2C). Here, SMYD3 is linked to cancer.